Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Busch

Showing results (651-660 of 678) with videos related to

Pageof 68
Sort By:
JAMA Surgery|October 8, 2025
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA TrialCaro L Bruna, Jony van Hilst, Maarten Korrel, et al.
BMC Cancer|August 7, 2023
Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trialJ L van Dam, E M M Verkolf, E N Dekker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2021
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS TrialBen M Eyck, J Jan B van Lanschot, Maarten C C M Hulshof, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 28, 2025
Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysisP C M Andel, I W J M van Goor, N C Biesma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2017
Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS TrialBo Jan Noordman, Mathilde G E Verdam, Sjoerd M Lagarde, et al.
Annals of Surgery|December 15, 2017
Alternative Fistula Risk Score for Pancreatoduodenectomy (a-FRS): Design and International External ValidationTimothy H Mungroop, L Bengt van Rijssen, David van Klaveren, et al.
Trials|April 9, 2017
Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trialThijs de Rooij, Jony van Hilst, Jantien A Vogel, et al.
Journal of the National Cancer Institute|September 3, 2025
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinomaAmmar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 TrialRuth A L Willems, Aniek E van Diepen, Esther N Dekker, et al.
International Journal of Cancer|April 10, 2020
Genome-wide association study identifies an early onset pancreatic cancer risk locusDaniele Campa, Manuel Gentiluomo, Ofure Obazee, et al.
Pageof 68

Showing results (651-660 of 678) with videos related to

Sort By:
Pageof 68
JAMA Surgery|October 8, 2025
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA TrialCaro L Bruna, Jony van Hilst, Maarten Korrel, et al.
BMC Cancer|August 7, 2023
Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trialJ L van Dam, E M M Verkolf, E N Dekker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2021
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS TrialBen M Eyck, J Jan B van Lanschot, Maarten C C M Hulshof, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 28, 2025
Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysisP C M Andel, I W J M van Goor, N C Biesma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2017
Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS TrialBo Jan Noordman, Mathilde G E Verdam, Sjoerd M Lagarde, et al.
Annals of Surgery|December 15, 2017
Alternative Fistula Risk Score for Pancreatoduodenectomy (a-FRS): Design and International External ValidationTimothy H Mungroop, L Bengt van Rijssen, David van Klaveren, et al.
Trials|April 9, 2017
Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trialThijs de Rooij, Jony van Hilst, Jantien A Vogel, et al.
Journal of the National Cancer Institute|September 3, 2025
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinomaAmmar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 TrialRuth A L Willems, Aniek E van Diepen, Esther N Dekker, et al.
International Journal of Cancer|April 10, 2020
Genome-wide association study identifies an early onset pancreatic cancer risk locusDaniele Campa, Manuel Gentiluomo, Ofure Obazee, et al.
Pageof 68